High Dose versus Standard Dose Chemotherapy for the Treatment of Breast Cancer
- 17 December 1995
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 770 (1), 288-304
- https://doi.org/10.1111/j.1749-6632.1995.tb31062.x
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.Journal of Clinical Oncology, 1995
- Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast CarcinomaNew England Journal of Medicine, 1994
- Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction.Journal of Clinical Oncology, 1994
- Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity.Journal of Clinical Oncology, 1994
- Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment.Journal of Clinical Oncology, 1994
- High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.Journal of Clinical Oncology, 1993
- Gene-marking to trace origin of relapse after autologous bone-marrow transplantationThe Lancet, 1993
- Interrupted versus Continuous Chemotherapy in Patients with Metastatic Breast CancerNew England Journal of Medicine, 1991
- Randomized Trial of Doxorubicin, Bisantrene, and Miltoxantrone in Advanced Breast Cancer: A Southwest Oncology Group StudyJNCI Journal of the National Cancer Institute, 1991
- Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.Journal of Clinical Oncology, 1987